I said "could" meaning I'm speculating just like in all other stocks. FOLD has a great pipeline and all I'm saying is that Friday's 26% haircut was unjustifiable. It has $106 million in cash and less than a million in debt. GSK is a huge collaborator and a 20% owner, bought an additional 3 million shares just last July at $6.30 per share. Who knows they could double down to lower their cost average. More data is coming and FOLD's Pompe platform is advancing. Even without Migalastat, FOLD is worth much more than it's current PPS. A bounce just like last December could be in the making.